MDGL · Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
1001 Conshohocken State Road, West Conshohocken, PA, 19428, United States
Biotechnology
Healthcare
Market Cap
9.803B
52 Wk Range
$353.54 - $615.00
Previous Close
$421.99
Open
$420.86
Volume
634,340
Day Range
$393.30 - $425.16
Enterprise Value
9.196B
Cash
961M
Avg Qtr Burn
N/A
Insider Ownership
5.80%
Institutional Own.
97.95%
Qtr Updated
Sep 30th 2026
